Analyst Ratings For NASDAQ:MLNT – Melinta Therapeutics (NASDAQ:MLNT)
Today, NASDAQ:MLNT – Melinta Therapeutics (NASDAQ:MLNT) stock received an upgrade by WBB Securities from Hold ➝ Buy with a price target of $8.00.
Some recent analyst ratings include
- 5/25/2018-WBB Securities Upgrade from a “Hold ➝ Buy” rating to a “” rating.
- 5/9/2018-Robert W. Baird Upgrade from a “Neutral ➝ Outperform” rating to a “” rating.
- 11/30/2017-Gabelli Upgrade from a “Sell ➝ Hold” rating to a “” rating.
- 11/30/2017-Ladenburg Thalmann Upgrade from a “Neutral ➝ Buy” rating to a “” rating.
- 10/26/2017-Jefferies Group Reiterated Rating of Hold ➝ Neutral.
- 8/10/2017-Roth Capital was Downgraded by analysts at Roth Capital from a “Buy ➝ Neutral” rating to a “” rating. They now have a $8.00 ➝ $4.00 price target on the stock.
- 8/10/2017-Stifel Nicolaus Reiterated Rating of Hold.
Recent Insider Trading Activity For NASDAQ:MLNT – Melinta Therapeutics (NASDAQ:MLNT)
NASDAQ:MLNT – Melinta Therapeutics (NASDAQ:MLNT) has insider ownership of 27.80% and institutional ownership of 58.65%.
- On 1/5/2018 Vatera Healthcare Partners Llc, Director, bought 5,777,778 with an average share price of $13.50 per share and the total transaction amounting to $78,000,003.00.
- On 3/8/2017 Dov A Md Goldstein, Director, sold 150,000 with an average share price of $3.55 per share and the total transaction amounting to $532,500.00.
- On 1/13/2017 Dov A Md Goldstein, Director, sold 105,460 with an average share price of $3.40 per share and the total transaction amounting to $358,564.00.
- On 1/6/2017 Dov A Md Goldstein, Director, sold 937,600 with an average share price of $3.41 per share and the total transaction amounting to $3,197,216.00.
- On 1/3/2017 David N Gill, Director, bought 5,000 with an average share price of $2.94 per share and the total transaction amounting to $14,700.00.
- On 3/1/2016 David Moore, Insider, bought 500 with an average share price of $16.18 per share and the total transaction amounting to $8,090.00.
- On 1/4/2016 Dov A. Md Goldstein, Director, sold 842 with an average share price of $30.06 per share and the total transaction amounting to $25,310.52.
Recent Trading Activity for NASDAQ:MLNT – Melinta Therapeutics (NASDAQ:MLNT)
Shares of NASDAQ:MLNT – Melinta Therapeutics closed the previous trading session at 6.47 up +1.17 22.03% with 6.550000190734863 shares trading hands.